Silo Pharma tops up with $815K private placement months after $3.5M raise
What's the deal? Silo PharmaDealroom has a profile for this one. Try Dealroom → closed a private placement on November 6, 2026, raising roughly $815,000 in net proceeds, according to a Form 8-K filing. It sold 136,005 common shares at $1.50 each and pre-funded warrants for up to 430,661 shares at $1.4999 apiece to accredited investors.
The details: The pre-funded warrants are immediately exercisable at a nominal $0.0001 per share. Holders cannot exceed 4.99% ownership after exercise — a cap that can rise to 9.99% with 61 days' notice. The company plans to use the money for working capital and general corporate purposes.
Silo also signed a registration rights agreement, committing to file a resale registration statement within 30 days. The filing was signed by chief executive officer Eric Weisblum.
Why now? This is a quick top-up, not a major financing. Silo's July private placement already brought in about $3.5 million net, with more possible if its warrants are exercised.
What could go wrong? The near-immediate share issuance from pre-funded warrants means dilution. The proceeds are modest against the company's needs: as of June 30, Silo reported $5.2 million in cash and short-term investments and $1.6 million of operating cash use in the first half of 2026.
The signal: For a company still advancing preclinical programs, the raise adds liquidity but ties to no clinical milestone. It extends runway at the margin rather than marking a pipeline advance.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
